You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Claims for Patent: 10,836,768

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,836,768

Title:	N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Abstract:	A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
Inventor(s):	Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
Assignee:	Ogeda SA
Application Number:	US16/204,390
Patent Claims:	1. A method for preventing and/or treating hot flashes in a patient, comprising administering to a patient in need thereof for at least four weeks a pharmaceutically effective amount of a compound selected from the group consisting of: wherein the frequency of hot flashes in the patient after at least four weeks of treatment is reduced compared to the frequency of hot flashes in the patient before at least four weeks of treatment. 2. The method according to claim 1, wherein the hot flashes are related to a condition selected from the group consisting of a perimenopausal condition, a menopausal condition, and a postmenopausal condition, or a combination thereof. 3. The method according to claim 1, wherein the hot flashes are a consequence of hormone therapy which intentionally lowers the level of sex hormones. 4. The method according to claim 3, wherein the hot flashes are selected from the group consisting of therapy-induced hot flashes in breast cancer, therapy-induced hot flashes in uterine cancer, and therapy-induced hot flashes in prostate cancer. 5. The method according to claim 1, wherein the compound is selected from the group consisting of: 6. The method according to claim 1, wherein the compound is: 7. A method for preventing and/or treating hot flashes in a patient, comprising administering to a patient in need thereof for at least four weeks a pharmaceutically effective amount of a compound selected from the group consisting of: wherein the severity of hot flashes in the patient after at least four weeks of treatment is reduced compared to the severity of hot flashes in the patient before at least four weeks of treatment. 8. The method according to claim 7, wherein the hot flashes are related to a condition selected from the group consisting of a perimenopausal condition, a menopausal condition, and a postmenopausal condition, or a combination thereof. 9. The method according to claim 7, wherein the hot flashes are a consequence of hormone therapy which intentionally lowers the level of sex hormones. 10. The method according to claim 9, wherein the hot flashes are selected from the group consisting of therapy-induced hot flashes in breast cancer, therapy-induced hot flashes in uterine cancer, and therapy-induced hot flashes in prostate cancer. 11. The method according to claim 7, wherein the compound is selected from the group consisting of: 12. The method according to claim 7, wherein the compound is:

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.